Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed or Refractory Follicular Lymphoma
NCT01849263Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2013
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ibrutinib in follicular lymphoma (FL), sponsored by National Cancer Institute. Started Apr 2013; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01849263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01849263.